Floatz logo

Nivolumab

Myelodysplastic Syndrome Acute Myeloid Leukemia

SCRI Development Innovations, LLCmonoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

79 Active assets in the Myelodysplastic Syndrome Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →